Delivery Order HHSN261201500024I-HHSN26100002
Award Date
9/19/16
Potential Completion Date
5/4/22
Potential Value
$1.3M
Federal Agency
National Cancer Institute
Awardee
IIT Research Institute
Ultimate Awardee
Illinois Institute Of Technology
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Chicago, IL 60616, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
4
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order awarded by the National Cancer Institute (NCI) to IIT Research Institute (IITRI), a non-profit preclinical contract research organization (CRO). The contract is for $532,562.26 to evaluate a breast cancer prevention agent under the PREVENT Cancer Preclinical Drug Development Program, a $149.995 million NCI Indefinite Delivery Vehicle (IDV) that IITRI holds. IITRI has extensive experience providing preclinical drug development services to federal agencies...
This federal contract award with award ID HHSN261201500024I|HHSN26100003 was issued by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services (HHS). The $321,110.80 award was made on September 15, 2016 to the IIT Research Institute (IITRI), a non-profit research organization and division of the Illinois Institute of Technology (IIT). The contract is for the "PRECLINICAL EVALUATION OF A NEW LIPID-BASED SMEDDS" under the NCI's PREVENT...
This federal contract award, valued at $33,483,214.15, was issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The contract is for preclinical pharmacology and toxicology studies to support the development of small molecule, biologic, and RNA therapeutic candidates across various disease areas. IITRI has extensive experience providing these services to...
This is a $1,010.00 firm fixed-price delivery order awarded by the National Cancer Institute (NCI) to the IIT Research Institute (IITRI), a non-profit contract research organization. The contract is for a "Kick Off Meeting, Preclinical Pharmacokinetic & Pharmacology Evaluations of Agents Being Developed for Cancer Patients" with a performance period from July 1, 2016 to September 30, 2016. This work is being performed under NCI's Pharmacokinetic and Pharmacology Evaluations for...
This is a Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The $23,349,236 contract is for the provision of preclinical in vitro and in vivo screening assays to support the development of cancer preventive agents. IITRI, which has extensive experience supporting the preclinical development of various therapeutics for federal...
This is a Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The $159,319,089.46 contract, which does not have a set-aside designation, is for preclinical toxicology and pharmacology studies to support Investigational New Drug (IND) applications for small molecule, biologic, and RNA therapeutic candidates across various...
This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The $4,145 contract is for a pre-clinical toxicology study of a drug developed for cancer patients, as part of the Toxicology of Drugs Developed for Cancer Patients contract vehicle. IITRI specializes in preclinical drug development services and has...
This is a $547,860 delivery order contract awarded by the National Cancer Institute (NCI) of the Department of Health and Human Services (HHS) to The Institute for Cancer Research, a non-profit research organization. The contract is part of the Preclinical Efficacy and Intermediate Endpoint Biomarkers indefinite delivery vehicle, which supports the PREVENT Cancer Preclinical Drug Development Program. Under this 5-year IDIQ, The Institute for Cancer Research provides preclinical efficacy...
This is a $718,265.00 delivery order awarded by the National Cancer Institute (NCI) of the Department of Health and Human Services (HHS) to IIT Research Institute, the research and technology development arm of Illinois Institute of Technology (IIT). The contract supports preclinical toxicology and pharmacology research for drugs developed for cancer patients, including exploratory studies of CCR4 CAR T cells. This work is performed under the NCI's "Toxicology of Drugs Developed for...
This is a $1,790,042.00 Delivery Order Contract awarded by the National Cancer Institute (NCI) to the IIT Research Institute (IITRI), a non-profit subsidiary of the Illinois Institute of Technology (IIT). The contract is for toxicology studies in mice and dogs administered MTX-531, which does not have a set-aside designation. IITRI is a leading preclinical contract research organization that specializes in providing drug development services to federal agencies like the NCI, NIAID, NINDS, and...